stockportfolio.pro
ARWR vs BMRN: Which Stock Is the Better Buy?
Arrowhead Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ARWR vs BMRN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | BioMarin Pharmaceutical Inc. (BMRN) | |
|---|---|---|
| Market cap | $10.0B | $10.9B |
| Revenue (latest FY) | $829.45M | $3.22B |
| Net income (latest FY) | $-1.63M | $348.90M |
| Revenue growth (5y CAGR) | 56.6% | 11.6% |
| Net margin | -0.2% | 10.8% |
| Return on equity | -0.3% | 5.7% |
| P/E ratio | — | 40.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 5 |
| Positive free cash flow | Yes | Yes |
See the full ARWR vs BMRN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ARWR's full financials → Open BMRN's full financials →More comparisons
Frequently asked questions
Which is bigger, ARWR or BMRN?
BioMarin Pharmaceutical Inc. is larger by market capitalization — $10.9B versus $10.0B.
Which grows faster, ARWR or BMRN?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus 11.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
ARWR fundamentals → · BMRN fundamentals → · All 1,500+ companies → · Free screener →